Primary and secondary prevention strategies among older postmenopausal women

Journal of Nurse-Midwifery

Volumn 43, Issue 4, 1998, Pages 262-272

  Keller, Colleen ^a   Fullerton, Judith ^a   Fleury, Julie ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DECISION MAKING; ESTROGEN THERAPY; FEMALE; HUMAN; LIFESTYLE; OSTEOPOROSIS; PHYSIOLOGY; POSTMENOPAUSE; REVIEW;

AGED; AGED, 80 AND OVER; COGNITION DISORDERS; CORONARY DISEASE; DECISION MAKING; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIFE STYLE; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 0032111115     PISSN: 00912182     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-2182(98)00014-7     Document Type: Article

References (132)

1. Johnson RJ, Wolinsky FD. Gender, race, and health: the structure of health status among older adults. Gerontology 1994;34: 24-35.
2. Katz SJ, Hofer TP. Socioeconomic disparities in preventive care persist despite universal coverage. Breast and cervical cancer screening in Ontario and the United States. JAMA 1994;272:53034.
3. Hopper SV. The influence of ethnicity on the health of older women. Clin Geriatr Med 1993;9:231-59.
4. Lichtman R. Perimenopausal and postmenopausal hormone replacement therapy. Part 1. An update of the literature on benefits and risks. J Nurse Midwifery 1996;41:3-28.
5. Ravnikar VA. Compliance with hormone replacement therapy. Are women receiving the full impact of hormone replacement therapy's preventive health benefits? Womens Health Issues 1992;2: 75-82.
6. Rothert M, Holmes-Royner M, Rovner D, et al. Health conse-quences of short- and long-term postmenopausal hormone therapy. Clin Chem 1996;48:1342-4.
7. Miller KL. Hormone replacement therapy in the elderly. Clin Obstet Gynecol 1996;39:912-32.
8. Jacobs S, Hillard TC. Hormone replacement therapy in the aged. A state of the art review. Drugs Aging 1996;8:193-213.
9. Rousseau ME. Women's midlife health: reframing menopause. J Nurse Midwifery 1998;43:208-23.
10. Wallace RB, Sherman BM, Bean JA, Treloar AE, Schlabaugh L. Probability of menopause with increasing duration of amenorrhea in middle-aged women. Am J Obstet Gynecol 1979; 135:1021-4.
11. Kaiser FE, Wilson MMG, Morley JE. Menopause/female sexual function. In: Cassel CK, Larson EB, Meier DE, Resnick NM, Rubenstein LZ, Sorensen LB, editors. Geriatric Medicine 3rd ed. New York: Springer, 1997:527-40
12. Mashchak CA, Kletzky OA, Artal R, Mishell DR Jr. The relation of physiological changes to subjective symptoms in postmenopausal women with and without hot flushes. Maturitas 1984;6:301308.
13. Breder CD, Dinarello CA, Saper CB. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988;240: 321-4.
14. Lichtman R. Perimenopausal and postmenopausal hormone replacement therapy. Part 2. Hormonal regimens and complementary and alternative therapies. J Nurse Midwifery 1996;41:195-210.
15. Avis NE, Brambilla D, McKinaly SM, Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol 1994;4:214-20.
16. Stewart DE, Boydell KM. Psychologic distress during menopause: associations across the reproductive life cycle. Int J Psychiatry Med 1993;23:157-62.
17. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
18. McGinnis JM, Lee PR. Healthy People 2000 at mid decade. JAMA 1995;273:1123-9.
19. Lipshitz DA. Nutrition. In: Cassel CK, Cohen HJ, Larson EB, etal, editors. New York: Springer, 1997;801-14.
20. McArdle WD, Katch FI, Katch VL. Exercise physiology: energy, nutrition and human performance. Philadelphia: Lea & Febiger, 1991.
21. McGinnis JM, Ballard-Barbash RM. Obesity in minority populations: policy implications of research. Am J Clin Nutr 1991;53 Suppl 6:1512S-14S.
22. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.
23. National Research Council. Nutrition Screening Initiative: Nutrition Screening Manual for Professionals Caring for Older Americans. Washington (DC): NRC, 1991.
24. Grundy SM, Balady GJ, Criqui MH, et al. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation 1997;95:2329-31.
25. Kris-Etherton PM. Cardiovascular disease: nutrition for prevention and treatment. Chicago: American Dietetic Association, 1990.
26. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10:493-6.
27. Bjorntorp P. Regional obesity. In: Bjorntorp P, Brodoff BN, editors. Obesity. Philadelphia (PA): Lippincott, 1992;579-86.
28. Anderson KM, Kannel WB. Obesity and disease. In: Bjorntorp B, Brodoff BN, editors. Obesity. Philadelphia (PA): Lippincott, 1992; 465-73.
29. Kaplan NM. The deadly quartet: upper body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514-20.
30. Folsom AR, Burke GL, Byers CL, et al. Implications of obesity for cardiovascular disease in blacks: the CARDIA and ARIC studies. Am J Clin Nutr 1991;53 Suppl 6:16045-11S.
31. Gillum RF. The associations of body fat distribution with hypertension, hypertensive heart disease, coronary heart disease, diabetes and cardiovascular risk factors in men and women, aged 18-77 years. J Chron Dis 1987;40:421-8.
32. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body fat distribution. Am J Clin Nutr 1992;55:950-4.
33. Shimokata H, Tobin JD, Muller DC, Elahi D, Coon PJ, Andres R. Studies in the distribution of body fat: I. Effects of age, sex, and obesity. J Gerontol 1989;44:M66-M73.
34. Wang Q, Hassager C, Ravn P, Wang S, Christiansen C. Total and regional body composition changes in early postmenopausal women: age-related or menopause-related? Am J Clin Nutr 1994;60: 843-8.
35. Lindsay R, Bush TL, Grady D, Speroff L, Lobo RA. Therapeutic controversy: estrogen replacement in menopause. J Clin Endocrinol Metab 1996;81:3829-38.
36. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
37. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.
38. Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking estrogen replacement therapy. Eur Heart J 1996; 17 Suppl D:9-14.
39. Grodstein F, Stampfer M, Colditz G, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
40. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994;83:693-700.
41. Manolio TA, Furberg CD, Shemanski L, et al. Progression of coronary artery disease: associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation 1993;88:2163-71.
42. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990; 150:2557-62.
43. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:1183-6.
44. Lee AJ, Löwe G Do, Woodward M, Tunstall-Pedoe H. Plasma fibrinogen are indicators of coronary heart disease. Perfusion 1991;4: 432.
45. Folsom AR, Wu KK, Shahar E, Davis CE. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993; 13:182936.
46. Meilahn EN, Kuller LH, Matthews KA, Kiss JE. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992;2:445-55.
47. Stefanick ML, Legault C, Tracy RP, et al. Distribution and correlates of plasma fibrinogen in middle-aged women: initial findings of the postmenopausal estrogen/progestin interventions (PEPI) study. Arterioscler Thromb Vase Biol 1995;15(12):2085-93.
48. Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995;86:306-16.
49. Barrett-Connor E, Miller V. Estrogens, lipids, and heart disease. Clin Geriatr Med 1993;9:57-67.
50. Teran AZ, Greenblatt RB, Chaddha JS. Changes in lipoproteins with various sex steroids. Obstet Gynecol Clin North Am 1987; 14:107-19.
51. Havel RJ. The formation of LDL: mechanisms and regulation. J Lipid Res 1984;25:1570-6.
52. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74-9.
53. Sherwin BB, Gelf MM. A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol 1989;73:759-66.
54. Wagner JD, Clarkson TB, St Clair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest 1991;88:1995-2002.
55. Jonas H, Kronmal R, Psaty B, et al. Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. CHS Collaborative Research Group Cardiovascular Health Study. Ann Epidemiol 1996;6:314-23.
56. Holm P, Stender S, Andersen H, Hansen B, Nordestgaard B. Antiatherogenic effect of estrogen abolished by balloon catheter injury in cholesterol-clamped rabbits. Arterioscler Thromb Vase Biol 1997; 17:1504-11.
57. Steinhaus LA, Dustman RE, Ruhling RO, et al. Aerobic capacity of older adults: a training study. J Sports Med Phys Fitness 1990;30:163-72.
58. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995;273:402-7.
59. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow up of participants in the Framingham Heart Study. Circulation 1983;67:968-77.
60. Lindheim SR, Notelovitz M, Feldman EB, Larsen S, Khan FY, Lobo RA. The independent effects of exercise and estrogen on lipids and lipoproteins in postmenopausal women. Obstet Gynecol 1994; 83:167-72.
61. Pi-Sunyer FX. Obesity. Determinants and therapeutic initiatives. Nutrition 1991;7:292-4.
62. Tuck ML, Sowers J, Dornfeld L. The effect of weight reduction on blood pressure, plasma renin activity and plasma aldosterone levels in obese patients. N Engl J Med 1981;304:930.
63. Dattilo AM, Kris-Etherton M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992; 56:320-8.
64. Ashley FW, Kännel WB. Relationship to weight change in atherogenic traits: the Framingham Study. J Chron Dis 1974;27:10314.
65. Hill JO, Peters JC, Reed GW, et al. Nutrient balance in humans: effects of diet composition. Am J Clin Nutr 1991;54:10-17.
66. Gey KF. Inverse correlation of vitamin E and ischémie heart disease. Int J Vit Nutr Res 1990;30:224-31.
67. Wähle KWJ, Duthrie GG. Lipoproteins, antioxidants and vascular disease. Eur J Clin Nutr 1991;45S:101-9.
68. Stampfer MJ, Hennekens CH, Manson JE. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-9.
69. Rimm EB, Stampfer MJ, Ascherio A. Vitamin E consumption and the risk of coronary artery disease in men. N Engl J Med 1993; 328:1450-6.
70. Hodis HN, Mack WJ, La Bree L. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary atherosclerosis. JAMA 1995;273:1849-54.
71. Stephens NG, Parsons A, Schofield PM. Randomized controlled trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
72. Losonczy KG, Harris TB, Havlik RJ. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the established populations for epidemiologic studies of the elderly. Am J Clin Nutr 1996-64:190-6.
73. Schwartz J, Freeman R, Frishman W. Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women. J Clin Pharmacol 1995;35:314-29.
74. Fillit H. Future therapeutic developments of estrogen use. J Clin Pharmacol 1995;35 Suppl 9:25S-8S.
75. Szklo M, Cerhan J, Diez-Roux AV, et al. Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1996; 144:1048-57.
76. Schmidt R, Fazekas F, Reinhart B, et al. Estrogen replacement therapy in older women: a neuropsychological and brain MRI study. J Am Geriatr Soc 1996;44:1307-13.
77. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports. Dementia 1995;6: 99-107.
78. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J 1994;41:361-71.
79. Chodzko-Zajko WJ. Physical fitness, cognitive performance, and aging. Med Sei Sports Exerc 1991;23:868-72.
80. Chodzko-Zajko WJ, Moore KA. Physical fitness and cognitive functioning in aging. Exerc Sport Sei Rev 1994-22:195-220.
81. Topp R, Stevenson JS. The effects of attendance and effort on outcomes among older adults in a long-term exercise program. Res Nurs Health 1994; 17:15-24.
82. Hill RD, Storandt M, Malley M. The impact of long-term exercise training on psychological function in older adults. J Gerontol 1993;48:12-7.
83. Rogers RL, Meyer JS, Mortel KF. After reaching retirement age physical activity sustains cerebral perfusion and cognition. J Am Geriatr Soc 1990;38:123-8.
84. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993;34:801-5.
85. Turner RT, Riggs BL, Speisberg TC. Skeletal effects of estrogen. Endocr Rev 1994;15(3):275-300.
86. Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993;341:797-801.
87. Weiss NS. Health consequences of short- and long-term postmenopausal hormone therapy. Clin Chem 1996;42:1342-4.
88. Weiss NS, Hill DA. Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Maturitas 1996;23: 235-9.
89. Samsioe G. Osteoporosis: an update. Acta Obstet Gynecol Scand 1997;76:189-99.
90. Lips P. Prevention of hip fractures: drug therapy. Bone 1996; 18 Suppl 3:159S-163S.
91. Haskell WL, Leon AS, Casperson CJ, et al. Cardiovascular benefits and assessment of physical activity and physical fitness in adults. Med Sei Sports Exerc 1992;24:S201-20.
92. Slemenda CW, Miller JZ, Hui SL, Reister TK, Johnston CC Jr. Role of physical activity in the development of skeletal mass in children. J Bone Miner Res 1991;6:1227-33.
93. Murphy S, Khaw KT, May H, Compston JE. Milk consumption and bone mineral density in middle aged and elderly women. BMJ 1994;308:939-41.
94. Smith EL, Reddan W, Smith PE. Physical activity and calcium modalities for bone mineral increase in aged women. Med Sei Sports Exerc 1981; 13:60-4.
95. Chow R, Harrison JE, Notarius C. Effect of two randomized exercise programs on bone mass of healthy post menopausal women. BMJ 1987;295:1141-4.
96. Krall EA, Dawson-Hughes B. Walking is related to bone density and rates of bone loss. Am J Med 1994:20-26.
97. Orwoll ES, Ferar J, Oviatt SK, McClung MR, Huntington K. The relationship of swimming exercise to bone mass in men and women. Arch Intern Med 1989; 149:2197-200.
98. National Institute of Health. Consensus Development Conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50.
99. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. JAMA 1996;276: 1404-8.
100. Bergkvist L, Persson I. Hormone replacement therapy and breast cancer. A review of current knowledge. Drug Safety 1996;5: 360-70.
101. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.
102. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332(24): 1589-93.
103. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42(6):832-38.
104. Kaufman DW, Palmer JR, de Mouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991;134:1375-85.
105. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987;257:209-15.
106. Speroff L. Postmenopausal hormone therapy and breast cancer. Obstet Gynecol 1996;87 Suppl 2:44S-54S.
107. Erwetz M. Hormone therapy in the menopause and breast cancer risk-a review. Maturitas 1996;23:241-6.
108. Garland CF, Friedlander NJ, Barrett-Connor E, Khan KT. Sex hormones and postmenopausal breast cancer: a prospective study in an adult community. Am J Epidemiol 1992; 135:1220-30.
109. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993; 168(5): 1473-80.
110. Armstrong BK. Oestrogen therapy after the menopauseboon or bane? Med J Aust 1988; 148:213-14.
111. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
112. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,807 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
113. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
114. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995; 142:788-95.
115. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141-6.
116. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a metaanalysis. Obstet Gynecol 1995;85:304-13.
117. Persson I, Yuen J, Bergkvist L, Adami HO, Hoover R, Schairer CL. Combined oestrogen-progestin replacement and breast cancer risk. Lancet 1992;340:1044.
118. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170:1213-23.
119. Eden J. Estrogen replacement therapy in survivors of breast cancer: a risk-benefit assessment. Drugs Aging 1996;8:127-33.
120. Wren B. Hormonal therapy and genital tract cancer. Curr Opin Obstet Gynecol 1996;8:38-41.
121. Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight reducing diet, with or without exercise in overweight men and women. N Engl J Med 1991; 325:461-6.
122. Haskell WL. Health consequences of physical activity: understanding and challenges regarding dose-response. Med Sei Sports Exerc 1994;26:649-60.
123. Hagberg JM. Exercise assessment of arthritic and elderly individuals. Baillière's Clin Rheumatol 1994;8:29-52.
124. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologie effects of transdermal estradiol. N Engl J Med 1986;314:1615-20.
125. Mandel FP, Geola FL, Meldrum DR, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol 1983;57:133-9.
126. Verdeal K, Ryan D. Naturally-occurring estrogens in plant foodstuffs: a review. J Food Protein 1979;42:577-83.
127. Miksicek RJ. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 1993;44:37-43.
128. Dwyer JT, Goldin BR, Saul N, Gualitieri L, Barakat S, Aldercreutz H. Tofu and soy drinks contain phytoestrogens. J Am Diet Assoc 1994;739-43.
129. Lee HP, Gourley L, Duffy SE, et al. Dietary effects on breast cancer risk in Singapore. Lancet 1991;337:1197-200.
130. Ho SC, Bacon WE, Harris T, Looker A, Magi S. Hip fracture rates in Hong Kong and the United States, 1988 through 1989. Am J Public Health 1993;83:694-7.
131. Lein LL, Lien EJ. Hormone therapy and phytoestrogens. J Clin Pharmacol Ther 1996;21:101-11.
132. American College Sports Medicine. Position stand. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscle fitness in healthy adults. Med Sei Sports Exerc 1990;22:265-74.